MedPageToday -- ORLANDO -- In a phase II trial, an investigational drug for Hodgkin lymphoma had a “dramatic response rate” in a cohort of patients who had failed previous therapy, a researcher reported here. Three-quarters of the patients treated with brentuximab vedotin had at least some reduction in the tumor burden and more than a third had a complete remission, according to Robert Chen, MD, of City of Hope National Medical Center in Duarte, Calif.
